A Phase III Randomized Trial for Patients with de novo

Project: Research project

Description

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) from Patients with High Allelic Ratio FLT2/ITD
StatusFinished
Effective start/end date1/30/1310/1/17

Funding

  • Children's Hospital of Philadelphia

Fingerprint

sorafenib
Bortezomib